Positive results from clinical trials, especially in Phase 2, generally lead to increased investor confidence and can significantly impact a biotech company's stock price. The announcement of these results being presented at a prestigious annual meeting like AAAAI further validates the potential of Deucrictibant and Pharvaris's position in the HAE treatment market. This news is likely to generate positive sentiment among investors, potentially leading to a short-term increase in PHVS stock price.